Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary M Pollack

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Pharmaceutical Research|June 3, 2006
Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cellsDavid L Bourdet, Gary M Pollack, Dhiren R Thakker
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 21, 2006
Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociceptionJ Cory Kalvass, Emily R Olson, Gary M Pollack
Pharmaceutical Research|November 24, 2004
Use of loperamide as a phenotypic probe of mdr1a status in CF-1 miceJ Cory Kalvass, Candace L Graff, Gary M Pollack
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 24, 2007
Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratiosJ Cory Kalvass, Tristan S Maurer, Gary M Pollack
Journal of Clinical Pharmacology|May 23, 2002
Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteersBindu R Murthy, Gary M Pollack, Kim L R Brouwer
American Journal of Pharmaceutical Education|September 6, 2007
Good outcome development is good scienceAdam M Persky, Wendy C Cox, Kim Deloatch, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2004
Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissuesChristopher J Matheny, Rabia Y Ali, Xiaodong Yang, et al.
Pharmaceutical Research|May 30, 2008
Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studiesGiulia Ghibellini, Elaine M Leslie, Gary M Pollack, et al.
Toxicology and Applied Pharmacology|May 5, 2009
Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteineSungkyoon Kim, David Kim, Gary M Pollack, et al.
British Journal of Clinical Pharmacology|April 20, 2004
Modelling the cardiovascular effects of ephedrineAdam M Persky, N Seth Berry, Gary M Pollack, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Pharmaceutical Research|June 3, 2006
Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cellsDavid L Bourdet, Gary M Pollack, Dhiren R Thakker
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 21, 2006
Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociceptionJ Cory Kalvass, Emily R Olson, Gary M Pollack
Pharmaceutical Research|November 24, 2004
Use of loperamide as a phenotypic probe of mdr1a status in CF-1 miceJ Cory Kalvass, Candace L Graff, Gary M Pollack
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 24, 2007
Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratiosJ Cory Kalvass, Tristan S Maurer, Gary M Pollack
Journal of Clinical Pharmacology|May 23, 2002
Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteersBindu R Murthy, Gary M Pollack, Kim L R Brouwer
American Journal of Pharmaceutical Education|September 6, 2007
Good outcome development is good scienceAdam M Persky, Wendy C Cox, Kim Deloatch, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2004
Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissuesChristopher J Matheny, Rabia Y Ali, Xiaodong Yang, et al.
Pharmaceutical Research|May 30, 2008
Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studiesGiulia Ghibellini, Elaine M Leslie, Gary M Pollack, et al.
Toxicology and Applied Pharmacology|May 5, 2009
Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteineSungkyoon Kim, David Kim, Gary M Pollack, et al.
British Journal of Clinical Pharmacology|April 20, 2004
Modelling the cardiovascular effects of ephedrineAdam M Persky, N Seth Berry, Gary M Pollack, et al.
Pageof 6